## Paolo Bruzzi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6163682/publications.pdf

Version: 2024-02-01

161	14,367	58 h-index	117
papers	citations		g-index
161	161	161	16824
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK FACTORS USING CASE-CONTROL DATA. American Journal of Epidemiology, 1985, 122, 904-914.	3.4	1,122
2	Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2000, 342, 1778-1785.	27.0	998
3	Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2007, 298, 405-12.	7.4	705
4	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	27.0	679
5	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood, 2001, 98, 2942-2947.	1.4	487
6	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase l–II study. Lancet Oncology, The, 2009, 10, 489-500.	10.7	458
7	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 2008, 100, 14-20.	6.3	344
8	Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 560-565.	2.0	326
9	Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2009, 119, 1703-1710.	1.6	296
10	Treatment of Advanced Squamous-Cell Carcinoma of the Head and Neck with Alternating Chemotherapy and Radiotherapy. New England Journal of Medicine, 1992, 327, 1115-1121.	27.0	285
11	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37†298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	13.7	260
12	Survival of metastatic breast carcinoma patients over a 20-year period. Cancer, 2005, 104, 1742-1750.	4.1	253
13	Falseâ€Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillinâ€∓azobactam. Clinical Infectious Diseases, 2004, 38, 913-916.	5.8	240
14	MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurology, The, 2013, 12, 669-676.	10.2	234
15	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology, 2012, 30, 2593-2600.	1.6	218
16	The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. Journal of the American College of Cardiology, 2005, 45, 1076-1080.	2.8	215
17	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A metaâ€analytic approach. Annals of Neurology, 2009, 65, 268-275.	5.3	206
18	Diagnostic Accuracy of Computed Tomographic Colonography for the Detection of Advanced Neoplasia in Individuals at Increased Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2453.	7.4	199

#	Article	IF	CITATIONS
19	Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. Journal of Clinical Oncology, 2014, 32, 3883-3891.	1.6	194
20	Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). Journal of Epidemiology and Community Health, 2006, 60, 412-416.	3.7	193
21	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 2006, 24, 3623-3628.	1.6	178
22	Risk associated with pregnancy in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 40, 1864-1869.	2.8	174
23	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 675-683.	7.7	169
24	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 2011, 29, 2144-2149.	1.6	167
25	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â€^×â€^2 factorial, randomised phase 3 trial. Lancet, The, 2015, 385, 1863-1872.	13.7	164
26	Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the <i>MYH</i> gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. International Journal of Cancer, 2004, 109, 680-684.	5.1	159
27	Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma. Journal of Clinical Oncology, 2003, 21, 1592-1601.	1.6	153
28	Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. Journal of the American College of Cardiology, 1995, 26, 380-387.	2.8	152
29	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood, 2005, 105, 2601-2607.	1.4	147
30	Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. Journal of the National Cancer Institute, 2005, 97, 1724-1733.	6.3	146
31	Transaortic Chordal Cutting. Journal of the American College of Cardiology, 2015, 66, 1687-1696.	2.8	141
32	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
33	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without <i>MYCN</i> Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
34	Retrospective Study of Childhood Ganglioneuroma. Journal of Clinical Oncology, 2008, 26, 1710-1716.	1.6	128
35	Infective Endocarditis in Hypertrophic Cardiomyopathy. Circulation, 1999, 99, 2132-2137.	1.6	125
36	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5117-5125.	1.6	114

#	Article	IF	CITATIONS
37	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	3.7	114
38	Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2010, 28, 2604-2611.	1.6	111
39	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. Cancer, 2004, 101, 704-712.	4.1	105
40	Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Cancer, 1992, 70, 1625-1633.	4.1	97
41	Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. Journal of Surgical Oncology, 2016, 113, 708-714.	1.7	94
42	Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors. Journal of Clinical Oncology, 1999, 17, 3596-3602.	1.6	89
43	Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. Journal of Clinical Oncology, 2009, 27, 5868-5873.	1.6	88
44	Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 2006, 24, 3912-3918.	1.6	85
45	Interobserver agreement in the histologic diagnosis of colorectal polyps the experience of the multicenter adenoma colorectal study (SMAC). Journal of Clinical Epidemiology, 2003, 56, 209-214.	5.0	83
46	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	5.3	80
47	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase l–II study from the Italian Sarcoma Group. European Journal of Cancer, 2014, 50, 784-792.	2.8	80
48	Effect of a palliative home care team on hospital admissions among patients with advanced cancer. Palliative Medicine, 2003, 17, 315-321.	3.1	74
49	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer, 2006, 13, 921-930.	3.1	74
50	Efficacy of Normal Saline Versus Heparinized Saline Solution for Locking Catheters of Totally Implantable Long-Term Central Vascular Access Devices in Adult Cancer Patients. Cancer Nursing, 2012, 35, E35-E42.	1.5	73
51	Twelve-year experience with left atrial resection in the treatment of non–small cell lung cancer. Annals of Thoracic Surgery, 2004, 78, 234-237.	1.3	72
52	Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design. Journal of Clinical Oncology, 2002, 20, 4150-4159.	1.6	69
53	Major and minor salivary glands tumours. Critical Reviews in Oncology/Hematology, 2003, 45, 215-225.	4.4	68
54	Attributable risks for oesophageal cancer in Northern Italy. European Journal of Cancer, 1992, 28, 1167-1171.	2.8	66

#	Article	IF	Citations
55	Association of Breast Cancer and Polymorphisms of Interleukin-10 and Tumor Necrosis Factor- $\hat{l}\pm$ Genes. Clinical Chemistry, 2003, 49, 1664-1667.	3.2	66
56	Cancer of the oropharynx. Critical Reviews in Oncology/Hematology, 2002, 41, 107-122.	4.4	63
57	TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2014, 9, 182.	2.7	62
58	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	2.1	61
59	MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology, 2002, 58, 417-421.	1.1	56
60	Malignant melanoma. Critical Reviews in Oncology/Hematology, 2003, 47, 35-63.	4.4	55
61	Can we measure long-term treatment effects in multiple sclerosis?. Nature Reviews Neurology, 2015, 11, 176-182.	10.1	55
62	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood, 2006, 107, 1591-1598.	1.4	53
63	Clinical Performance of the $(1,3)$ - $\hat{l}^2$ - $\langle scp \rangle d \langle scp \rangle$ -Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections. Vaccine Journal, 2011, 18, 2113-2117.	3.1	53
64	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial;) Tj ETQq0	0 02r.gBT /0	Overzock 10 T
65	Cancer of the nasopharynx. Critical Reviews in Oncology/Hematology, 2003, 45, 199-214.	4.4	50
66	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer, 2005, 104, 2099-2103.	4.1	50
67	Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. European Journal of Cancer, 2010, 46, 198-206.	2.8	50
68	Divergent determinants of 18F–NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. International Journal of Cardiovascular Imaging, 2014, 30, 439-447.	1.5	47
69	Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial. Annals of Surgical Oncology, 2016, 23, 2494-2500.	1.5	45
70	Anthropometric variables and risk of breast cancer. International Journal of Cancer, 1990, 45, 397-402.	5.1	43
71	Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Scientific Reports, 2016, 6, 19569.	3.3	43
72	Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. Annals of Surgical Oncology, 2022, 29, 5732-5744.	1.5	43

#	Article	IF	CITATIONS
73	Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Gastrointestinal Endoscopy, 1997, 46, 124-130.	1.0	42
74	Metabolic Treatment with <i>L</i> -Carnitine in Acute Anterior ST Segment Elevation Myocardial Infarction. Cardiology, 2006, 106, 215-223.	1.4	42
75	SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast, 2016, 30, 197-200.	2.2	42
76	An extended assessment of bowel habits in a general population. World Journal of Gastroenterology, 2004, 10, 713.	3.3	41
77	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. European Journal of Cancer, 2017, 71, 34-42.	2.8	39
78	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Research and Treatment, 2015, 150, 405-413.	2.5	38
79	Prognostic role of lymph-node level involvement in patients undergoing axillary dissection for breast cancer. European Journal of Surgical Oncology, 1998, 24, 104-109.	1.0	36
80	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 359-365.	2.0	36
81	High expression of 90K (Macâ€2 BP) is associated with poor survival in nodeâ€negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36
82	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)., 2019, 7, 96.		34
83	Novel germlineAPC variants in patients with multiple adenomas. Genes Chromosomes and Cancer, 1998, 22, 257-267.	2.8	33
84	Population attributable risk for endometrial cancer in Northern Italy. European Journal of Cancer & Clinical Oncology, 1989, 25, 1451-1456.	0.7	32
85	The impact of received dose intensity on the outcome of advanced ovarian cancer. European Journal of Cancer, 1993, 29, 181-184.	2.8	32
86	Bladder cancer. Critical Reviews in Oncology/Hematology, 2002, 41, 89-106.	4.4	32
87	Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. Oncologist, 2008, 13, 1137-1148.	3.7	31
88	CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus. Biology of Blood and Marrow Transplantation, 2012, 18, 92-99.	2.0	31
89	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1036-1043.	7.0	31
90	Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology, 1994, 49, 333-339.	2.5	30

#	Article	IF	Citations
91	Mathematical modelling of photomineralization of phenols in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide. Chemosphere, 1996, 33, 2159-2173.	8.2	30
92	Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. European Journal of Cancer, 1993, 29, 1658-1663.	2.8	28
93	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. Journal of the National Cancer Institute, 2011, 103, 1529-1539.	6.3	27
94	Antioxidant supplement and long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized trial. Journal of Gastroenterology, 2013, 48, 698-705.	5.1	27
95	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemotherapy and Pharmacology, 2014, 73, 299-307.	2.3	27
96	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	6.4	27
97	Vatalanib in Advanced Colorectal Cancer: Two Studies With Identical Results. Journal of Clinical Oncology, 2011, 29, 1938-1940.	1.6	26
98	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1566.	2.4	26
99	Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration. Radiology, 2014, 271, 805-813.	7.3	24
100	Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 622-625.	0.7	23
101	The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis. Journal of Neurology, 2005, 252, 1455-1458.	3.6	23
102	Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement. Public Health Genomics, 2015, 18, 225-232.	1.0	23
103	Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients. Oncotarget, 2016, 7, 26465-26479.	1.8	23
104	Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1862-1867.	2.5	22
105	Mathematical modelling of pilot-plant photomineralization of chlorophenols in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide. Chemosphere, 1997, 34, 41-49.	8.2	21
106	Do patients with rectosigmoid adenomas 5 mm or less in diameter need total colonoscopy?. Gastrointestinal Endoscopy, 1999, 50, 314-321.	1.0	20
107	Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. Journal of Antimicrobial Chemotherapy, 2013, 68, 1862-1871.	3.0	20
108	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 2016, 159, 79-86.	2.5	20

#	Article	IF	Citations
109	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer, 2013, 13, 164.	2.6	19
110	Clinical Application of Micronucleus Test: A Case-Control Study on the Prediction of Breast Cancer Risk/Susceptibility. PLoS ONE, 2014, 9, e112354.	2.5	19
111	CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. Annals of Hematology, 2010, 89, 613-618.	1.8	18
112	Micronucleus test for radiation biodosimetry in mass casualty events: Evaluation of visual and automated scoring. Radiation Measurements, 2011, 46, 169-175.	1.4	18
113	Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer. International Journal of Molecular Sciences, 2013, 14, 9686-9702.	4.1	18
114	Role of Preoperative Cardiovascular Magnetic Resonance in Planning Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 123, 1517-1526.	1.6	18
115	The Relationship Between Oral Contraceptive Use, Cancer and Vascular Disease. Drug Safety, 1990, 5, 436-446.	3.2	17
116	Refining sorafenib therapy: lessons from clinical practice. Future Oncology, 2015, 11, 449-465.	2.4	17
117	Pegfilgrastim administration after 24 or 72 or 96Âh to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. Supportive Care in Cancer, 2016, 24, 1285-1294.	2.2	17
118	Non-drug industry funded research. BMJ: British Medical Journal, 2008, 336, 1-2.	2.3	16
119	Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation. Journal of Obstetrics and Gynaecology, 2016, 36, 783-788.	0.9	16
120	Reporting of subgroup analyses from clinical trials. Lancet Neurology, The, 2012, 11, 747.	10.2	15
121	Congenital Muscular Mitral-Aortic Discontinuity Identified in Patients With ObstructiveÂHypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, 2238-2247.	2.8	15
122	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Research and Treatment, 2020, 181, 61-68.	2.5	15
123	Phase II Study of Combined Immunotherapy, Chemotherapy, and Radiotherapy in the Postoperative Treatment of Advanced Non–Small–Cell Lung Cancer. Journal of Immunotherapy, 2000, 23, 161-167.	2.4	15
124	Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. Scientific Reports, 2017, 7, 14159.	3.3	14
125	Different View on Larynx Preservation Evidence-Based Treatment Recommendations. Journal of Clinical Oncology, 2018, 36, 1376-1377.	1.6	14
126	NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy. Contemporary Clinical Trials Communications, 2020, 17, 100496.	1.1	14

#	Article	IF	Citations
127	Pilot-plant photomineralization of dichloromethane and tetrachloroethene in aqueous solution, by photocatalytic membranes immobilizing titanium dioxide and photopromoters. Chemosphere, 1996, 33, 1531-1542.	8.2	13
128	Is there a subset of patients with preoperatively diagnosed N2 non–small cell lung cancer who might benefit from surgical resection?. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 849-858.	0.8	13
129	Bevacizumab Plus Fluorouracil: The Value of Being Part of a Developing Story. Journal of Clinical Oncology, 2005, 23, 3660-3662.	1.6	12
130	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 131-136.	2.5	12
131	Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and $\hat{I}^2$ 2-microglobulin downregulation in breast cancer. Human Immunology, 2009, 70, 492-495.	2.4	12
132	The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits. Digestive and Liver Disease, 2010, 42, 99-102.	0.9	12
133	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. Breast Cancer Research and Treatment, 2016, 155, 117-126.	2.5	12
134	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. Journal of Cellular Biochemistry, 2000, 76, 311-321.	2.6	10
135	Comparison of coronary flow reserve estimated by dynamic radionuclide SPECT and multi-detector x-ray CT. Journal of Nuclear Cardiology, 2017, 24, 1712-1721.	2.1	10
136	The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. European Journal of Cancer, 2017, 83, 324-328.	2.8	10
137	Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer, 2002, 95, 228-235.	4.1	9
138	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). Oncology, 2020, 98, 763-770.	1.9	9
139	A Multicenter Study of Colorectal Adenomas Rationale, Objectives, Methods and Characteristics of the Study Cohort. Tumori, 1995, 81, 157-163.	1.1	8
140	Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients. Journal of the National Cancer Institute Monographs, 2011, 2011, 142-146.	2.1	8
141	Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study. PLoS ONE, 2018, 13, e0197522.	2.5	8
142	Some Further Consideration on the Role of Oral Contraceptives in Breast Carcinogenesis. Tumori, 1990, 76, 220-224.	1.1	7
143	Objective Response to Treatment as a Potential Surrogate Marker of Survival in Breast Cancer. Annals of the New York Academy of Sciences, 2002, 963, 144-147.	3.8	7
144	Prognostic Effect of DNA Aneuploidy from Bladder Washings in Superficial Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 979-983.	2.5	7

#	Article	IF	Citations
145	Molecular epidemiology: New rules for new tools?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 600, 3-11.	1.0	6
146	The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations. European Journal of Human Genetics, 2014, 22, 280-282.	2.8	6
147	Added prognostic value of ischaemic threshold in radionuclide myocardial perfusion imaging: a common-sense integration of exercise tolerance and ischaemia severity. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 750-760.	6.4	5
148	Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach. JAMA Neurology, 2022, 79, 821.	9.0	5
149	Follow-up Studies of Patients with Categorized Breast Cysts Annals of the New York Academy of Sciences, 1990, 586, 43-48.	3 <b>.</b> 8	4
150	Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients. European Journal of Surgical Oncology, 2021, 47, 1920-1927.	1.0	4
151	Wolfe's mammographic patterns in women with Gross Cystic Disease of the breast. Journal of Clinical Epidemiology, 1995, 48, 969-976.	5.0	3
152	Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2007, 99, 1050-1051.	6.3	3
153	The General Practitioner's Management of Patients With a New Diagnosis of Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2006, 40, 87.	2.2	2
154	Screening women at intermediate risk: harm or charm?. European Journal of Radiology, 2012, 81, S116-S117.	2.6	2
155	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). ESMO Open, 2016, 1, e000109.	4.5	2
156	Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer. Breast Care, 2021, 16, 299-306.	1.4	2
157	Prognostic factors in chronic subdural hematoma: results from a monocentric consecutive surgical series of 605 patients. Journal of Neurosurgical Sciences, 2021, 65, 14-23.	0.6	2
158	An Unconventional Cancer Treatment Lacking Clinical Efficacy Remains Available to Italian Cancer Patients. Tumori, 2008, 94, 830-832.	1,1	1
159	Reply to M.L. Berger et al. Journal of Clinical Oncology, 2010, 28, e345-e345.	1.6	1
160	Comments on "evidence for acute neurotoxicity after chemotherapy― Annals of Neurology, 2011, 69, 1064-1064.	5 <b>.</b> 3	0
161	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. Oncologist, 2013, 18, 924-925.	3.7	0